Tracking heart recovery with AI-read ECGs after ablation for atrial fibrillation and heart failure
Follows adults with atrial fibrillation and heart failure after catheter ablation using AI-read ECGs.
Key facts
- Who runs it
- Ewha Womans University Mokdong Hospital
- Where
- Seoul, South KoreaSee the site
- Trial code
- Registry title
- An AI-ECG-Based Approach for Dynamic Assessment of Heart Failure Risk and Myocardial Recovery Following Atrial Fibrillation Ablation
- Status
- Not yet recruiting
- People taking part
- 1,000 people, planned
- Starts
- 1 Jan 2027
- Expected to end
- 31 Dec 2029
- Type of study
- Observational
- Record updated
- 20 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with symptomatic atrial fibrillation and mildly reduced heart pumping function who are about to have their first catheter ablation.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Symptomatic paroxysmal or persistent atrial fibrillation. Left ventricular ejection fraction between 41% and 49%, plus at least one sign of hidden heart failure (for example elevated NT-proBNP, left atrial volume index >34 mL/m², average E/e' ≥14, reduced global longitudinal strain, mild pulmonary hypertension, or exertional intolerance suggestive of early heart failure).
- Earlier treatment
- First-time catheter ablation for atrial fibrillation, scheduled. Cannot have had an earlier atrial fibrillation catheter ablation.
- Biomarker or test result
- At least one analyzable sinus rhythm 12-lead ECG before ablation. Left ventricular ejection fraction measured by echocardiography within 3 months before ablation.
Main reasons for not taking part
- Left ventricular ejection fraction of 40% or lower
- Previous atrial fibrillation catheter ablation
- Significant valvular heart disease requiring intervention
- Hypertrophic or infiltrative cardiomyopathy
- Acute coronary syndrome, coronary revascularization, or myocarditis within 3 months
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Age ≥18 years
- Symptomatic paroxysmal or persistent atrial fibrillation
- Scheduled for first-time catheter ablation
- Left ventricular ejection fraction between 41% and 49% measured by transthoracic echocardiography within 3 months before ablation
- At least one analyzable sinus rhythm 12-lead electrocardiogram before ablation
- At least one latent heart failure substrate feature:; Elevated NT-proBNP; Increased left atrial volume index (>34 mL/m²); Average E/e' ≥14; Reduced global longitudinal strain; Mild pulmonary hypertension; Exertional intolerance suggestive of early heart failure
- Ability to provide written informed consent
Who cannot take part
- Previous atrial fibrillation catheter ablation
- Significant valvular heart disease requiring intervention
- Acute coronary syndrome, coronary revascularization, or myocarditis within 3 months
- Active malignancy with life expectancy <1 year
- Left ventricular ejection fraction ≤40%
- Hypertrophic or infiltrative cardiomyopathy
- Severe renal dysfunction requiring dialysis
- Inadequate electrocardiographic or echocardiographic image quality
- Pregnancy
- Inability or unwillingness to provide written informed consent
Where in South Korea
- Ewha Womans University Mokdong HospitalSeoul, South KoreaContact: Yeji Kim, PhDNot yet recruiting
About the trial
What the trial wants to find out
Background Artificial intelligence-enabled electrocardiography (AI-ECG) has emerged as a promising digital biomarker for detecting latent myocardial dysfunction and predicting cardiovascular risk. However, whether serial AI-derived risk estimates reflect myocardial recovery following therapeutic intervention remains unknown.
Read full original descriptionShow less
Objective The DYNAMIC-AF HF Study aims to evaluate longitudinal changes in AI-ECG-derived heart failure (HF) risk after catheter ablation in patients with atrial fibrillation (AF) and heart failure with mildly reduced ejection fraction (HFmrEF), and to determine their association with conventional markers of reverse remodeling.
Methods The DYNAMIC-AF HF Study is a prospective multicenter observational cohort study enrolling 1,000 patients with symptomatic AF and HFmrEF undergoing first-time catheter ablation. Eligible participants must have a left ventricular ejection fraction of 41-49% and at least one predefined HF-related feature suggestive of latent myocardial dysfunction. Serial 12-lead electrocardiograms, echocardiography, biomarker assessments, and clinical follow-up will be performed at baseline and at 3, 6, and 12 months. AI-based ECG analysis will generate continuous HF-risk scores, enabling construction of longitudinal AI-derived HF risk trajectories. The primary endpoint is the change in AI-derived HF risk from baseline to 12 months. Secondary endpoints include changes in left ventricular ejection fraction, global longitudinal strain, N-terminal pro-B-type natriuretic peptide levels, AF recurrence, HF hospitalization, and mortality.
Conclusions This study will evaluate whether serial AI-ECG assessment can serve as a dynamic digital biomarker of myocardial recovery following AF ablation and support future AI-enabled monitoring and clinical decision-support strategies in cardiovascular care.
The group in the trial
- AF-HFmrEF Cohort
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- DYNAMIC-AF HF Study: An AI-ECG-Based Approach for Dynamic Assessment of Heart Failure Risk and Myocardial Recovery Following Atrial Fibrillation Ablation
- Plain-language title
- Tracking heart recovery with AI-read ECGs after ablation for atrial fibrillation and heart failureGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 20 July 2026